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MIF gene rs755622 polymorphism 
positively associated with acute 
coronary syndrome in Chinese Han 
population: case–control study
Guo-Li Du1,2,3,7, Jun-Yi Luo1,4,7, Duolao Wang5, Yan-Hong Li1,4,6, Bin-Bin Fang1,4,  
Xiao-Mei Li1,4*, Xiao-Ming Gao1,3,4* & Yi-Ning Yang  1,4*
Macrophage migration inhibitory factor (MIF) has been recognized as a major player in the pathogenesis 
of atherosclerosis. This study determined the association between polymorphisms of MIF gene and 
acute coronary syndrome (ACS). The polymorphism of MIF gene (rs755622, rs1007888 and rs2096525) 
was analyzed in 1153 healthy controls and 699 ACS cases in Chinese Han population. Plasma MIF level 
was also measured in part of ACS patients (139/19.9%) and healthy controls (129/11.2%) randomly. 
Most participants including healthy controls and ACS patients carried rs755622 GG (63.1% vs. 56.7%) 
and CG genotypes (33.1% vs. 38.9%) and G allele of rs755622 (79.6% vs. 76.1%, respectively), while CC 
genotype (3.8% vs. 4.4%) and C allele (20.4% vs. 23.9%) carriers were the lowest. Multivariate logistic 
regression analysis showed that carriers with rs755622 C allele had a higher risk of ACS compared to 
other genotypes (AOR = 1.278, 95% CI: 1.042–1.567). In addition, CC genotype carriers had the highest 
plasma levels of MIF than other genotype carriers. The MIF level in ACS patients with CC genotype 
was significantly higher than ACS patients carrying GG genotype and healthy controls carrying 3 
different genotypes of MIF gene rs755622. Our findings indicate that MIF gene rs755622 variant C allele 
is associated with increased risk of ACS. Identification of this MIF gene polymorphism may help for 
predicting the risk of ACS.
Coronary artery disease (CAD) is the leading cause of mortality worldwide, accounting for about 30% of deaths 
globally in 2012 and approximately 70% of deaths in developing countries1. Acute coronary syndrome (ACS) 
is an urgent condition of CAD due to a rupture of the atherosclerotic plaque in coronary arteries. The com-
plexity of CAD pathogenesis poses significant challenges to decision making for effective interventions. Use of 
multi-marker algorithms including biological markers and genetic markers will improve prediction of CAD risk 
in clinic2.
Inflammation plays critical roles in CAD and participates pivotally in almost every stage of atherosclerosis 
including initiation, progression and destabilization of plaque and myocardial infarction3. MIF is produced by 
different cell types such as immune cells (monocytes, macrophages and lymphocytes) and endocrine, endothelial 
and epithelial cells4. It has been proved that MIF plays an essential role in a variety of acute and chronic inflam-
matory disorders5,6 as well as in cancer7,8. Previous studies have also revealed a critical role of MIF in atheroscle-
rosis9,10, therefore, MIF is very likely associated with the risk of ACS.
The human MIF gene locates at chromosome region 22q11.2 comprising approximately 800 nucleotides and 
containing 3 exons and 2 introns11. At least five single nucleotide polymorphisms (SNPs) in the human MIF gene 
locating at -173G/C (rs755622), +254 (rs2096525), +656 (rs2070766), 3.8 kb 3′ of the translation termination 
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codon (rs1007888) and -794 CATT5-8 microsatellite have been mainly reported. Loci rs2096525 and rs2070766 
locate at introns, rs755622 and -794 CATT5-8 locate at the promoter region of MIF and rs1007888 located in the 
3′ flanking region of the MIF gene. Of them, -173G/C (rs755622) and -794 CATT5-8 have been reported to be 
associated with CAD12–14.
Xinjiang, the northwest part of China, is a region with multiple ethnic populations. People living in Xinjiang 
have some special life styles and habits which are different from other regions of China, for example more meat, 
dairy products and alcohol consumption. Our previous epidemiological investigation revealed the prevalence of 
hypertension (33.4%15 vs. 27.9%16), dyslipidemia (53.3%17 vs. 40.4%16), type-2 diabetes (9.26%18 vs. 5.5%19) and 
obesity [(1082/5757, unpublished data) vs. 11.9%16] in Chinese Han population in Xinjiang were higher than 
other parts of China. It is expected that a higher prevalence of CAD in Xinjiang with an association of the higher 
prevalence of all major risk factors i.e. hypertension, dyslipidemia, diabetes and obesity. Moreover, a significant 
difference in prevalence of major cardiovascular risk factors and adverse risk profiles among different ethnic 
groups in Xinjiang has been reported20. We have previously demonstrated that there was a significant associa-
tion between the polymorphism of MIF gene -173G/C (rs755622) and CAD and severity of coronary lesions in 
Chinese Kazakh population13. Considering potential genetic influence and MIF as a key factor in atherosclerotic 
plaque formation, in this study, we investigate, in Han Chinese population, whether the variants of MIF gene 
predispose to ACS and have function influence on circulating plasma MIF level in both healthy controls and ACS 
patients.
Materials and Methods
Ethic declaration. This study was approved by the Ethics Committee of the First Affiliated Hospital of 
Xinjiang Medical University (Urumqi, China) and conducted according to the standards of the Declaration of 
Helsinki and written informed consents were obtained from all of the participants.
Study population. In this unmatched case-control study, we recruited adult patients with ACS patients 
from Chinese Han population who lived in Xinjiang from 2008 to 2013. The patients presenting with persistent 
chest pain more than 20 min, typical electrocardiographic changes including new pathologic Q waves and ST 
segment elevation more than 1 mm, and increased plasma levels of creatinine kinase-MB isoenzyme (CK-MB) 
(more than 2-fold higher than the upper reference limit) and/or troponin-T more than 0.1 μg/ml according to the 
guidelines21. All ACS patients included underwent coronary angiography to confirm the ACS diagnosis, exem-
plified with identifiable culprit-vessel, i.e. ≥50% luminal stenosis in at least one coronary artery or major branch 
segments. Patients were excluded if they had regional wall motion abnormalities, relevant valvular abnormalities 
in echocardiograms, acute inflammatory diseases, tumors, autoimmune disease and severe hepatic and renal 
dysfunction.
The control participants were recruited from the cardiovascular risk survey study and had no evidence of 
cardiovascular and other systemic disease as determined on history, physical examination, blood test and ECG 
recording. The design of this study has been previously reported13,22.
Biochemical assays. Venous blood samples were drawn at the catheter laboratory before angiogra-
phy from ACS patients and from healthy controls during medical examination. Blood biochemistry includ-
ing total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C) and high-density 
lipoprotein-cholesterol (HDL-C) in all participants were performed using the commercially available auto-
mated platform (Dimension AR/AVL Clinical Chemistry System, DADE Bchring, Newark, NJ), in the Central 
Laboratory of the First Affiliated Hospital of Xinjiang Medical University. We also randomly selected some ACS 
patients and healthy controls to test plasma MIF levels by using enzyme linked immunosorbent assay (ELISA). 
The randomization of participants selection was computer generated at the Key Laboratory of Cardiovascular 
Disease Research of Xinjiang Medical University (blocked randomization) and the participants’ allocations 
were kept in sequentially numbered and sealed envelopes. Plasma MIF levels were measured using Quantikine 
MIF ELISA kits (R&D Systems, USA) according to manufacturer’s specifications at Xinjiang Key Laboratory of 
Cardiovascular Disease Research.
Polymorphisms selection. A total of three SNPs (rs755622, rs1007888, and rs2096525) of the MIF gene 
whose minor allele frequencies (MAF) are more than 0.1 were selected from the HapMap human SNP database 
(www.hapmap.org). The rs755622 locates in the promoter region, rs1007888 locates in the translation termination 
codon and rs2096525 locates in the first intron of MIF gene. We also found that the above three SNPs were the 
tagging SNP of the Chinese Han population (MAF ≥ 0.1 and with r2 ≥ 0.8 as a cut-off in linkage disequilibrium 
pattern analysis) in the HapMap.
Genotyping of MIF gene. Genomic DNA was extracted from the peripheral leukocytes using standard 
phenol-chloroform method and stored at −80 °C for future analysis. We analyzed the polymorphism of MIF 
gene using the TaqMan® SNP genotyping assay (Applied Biosystems). The primers and probes used in the assay 
were chosen according to the information at the ABI website (http://myscience.appliedbiosystems.com). We uti-
lized the Applied Biosystems7900HT Standard Real-Time PCR System to amplify genomic DNA. The results 
of each polymorphism of MIF gene were read by the Sequence Detection Systems (SDS) automation controller 
software v2.3 (ABI). The reaction system of PCR amplification was as follows: 3 μL of TaqMan Universal Master 
Mix, 0.12 μL probes and 1.88 ddH2O in a 6 μL final reaction volume containing 1 μL DNA (50 ng). Amplification 
cycling conditions were as follows: 95 °C for 5 min; 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Samples with 
ambiguous genotypes that were not separated by discrete clusters were re-genotyped as we described previously13.
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Definition of Cardiovascular Risk Factors. The formula, body weight (kg)/height (m2) was used to calcu-
late the body mass index (BMI). Overweight/obesity was classified as a BMI ≥ 24 kg/m2. Hypertension was defined 
as history of hypertension and/or repeated systemic blood pressure measurements exceeding 140/90 mmHg. 
Diabetes was defined as history or presence of diabetes and/or a fasting plasma glucose level ≥ 7.0 mmol/L 
(126 mg/dL) or a random glucose value ≥ 11.1 mmol/L (200 mg/dL) or a 2-hour plasma glucose ≥ 11.1 mmol/L 
during an oral glucose tolerance test (OGTT) plus signs or symptoms of diabetes. If there is no signs or symp-
toms of diabetes, the glucose level should be examined on another day. Concentrations of glucose ≥ 6.1 mmol/L, 
TC ≥ 5.20 mmol/L, TG ≥ 1.71 mmol/L, LDL-C ≥ 3.10 mmol/L, and HDLC < 1.04 mmol/L were defined as hyper-
glycemia, hypercholesterolemia, hypertriglyceridemia, hyper-LDL-C or hypo-HDL-C, respectively.
Statistical analyses. Data analysis was performed using the SPSS version 21.0 (Chicago, IL, USA). We 
calculated the sample size according to the formula of unmatched case-control study23 and previous data13. 
Continuous variables were expressed as mean ± standard deviation (SD) and compared using the unpaired 
Student t test between ACS group and control group. Categorical variables were compared using the Chi-square 
test. We also used Chi-square test in Hardy-Weinberg equilibrium (HWE) to compare the frequencies of geno-
types and alleles between ACS patients and control participants.
We used logistic regression models to analyze association between MIF gene polymorphisms and ACS in two 
steps. We first fitted a univariate logistic regression model to evaluate association between rs755622 together each 
of the variables listed in Table 1 and ACS. We then perofrmed a multivariate logistic regression model to assess 
the association between MIF gene polymorphisms and ACS controlling for possible confounding factors used in 
the univariate analysis. Crude odds ratios (COR) and adjusted odds ratios (AOR) were calculated along with 95% 
confidence intervals (CIs). Statistical significance was set at P < 0.05.
Results
Demographic and clinical characteristics of participants. A total of 699 ACS patients (mean age 
59.1 ± 10.1 years and 61.7% men) and 1153 healthy controls (mean age 58.7 ± 11.1 years and 55.1% men) were 
recruited in the present study. Demographic and clinical characteristics of all participants are summarized in 
Table 1. ACS patients were older and had greater BMI and levels of glucose, LDL-C and TG and higher prevalence 
of hypertension, diabetes, hyperglycemia, hypercholesteremia and hyper-LDL-C but lower HDL-C level com-
pared to healthy controls (all P < 0.05).
MIF gene polymorphism rs755622 positively associated with ACS. Three SNPs of MIF (rs755622, 
rs1007888, and rs2096525) were successfully genotyped in all ACS patients and healthy controls (Table 2). The 
MAF of rs755622, rs1007888 and rs2096525 were 0.239, 0.483 and 0.212, respectively. All the genotype frequen-
cies were in Hardy-Weinberg equilibrium (HWE, P > 0.05). There was no significant difference in distribution of 
genotypes or alleles rates in rs1007888 and rs2096525 between ACS and control groups (P > 0.05). However, we 
found significant differences of genotypic and allelic distribution in rs755622. The frequency of the CC genotype 
in ACS patients was higher than that in control subjects (4.4% vs. 3.8%, P = 0.024). Moreover, the frequency of the 
C allele was also higher in the ACS than that in control group (23.9% vs. 20.4%, P = 0.012).
Characteristics
Control 
(n = 1153)
ACS 
(n = 699) P-Value
Age (years) 58.7 ± 11.1 59.1 ± 10.1 0.001
Male, n (%) 635 (55.1) 431 (61.7) 0.005
BMI (kg/m2) 25.7 ± 3.1* 26 ± 2.9 0.028
Overweight and obesity (BMI ≥ 24 kg/m2) 795 (69.0)* 531 (76.0) 0.001
Smoking, n (%) 834 (72.3) 439 (62.8) <0.001
Hypertension, n (%) 719 (37.6) 348 (50.2) <0.001
Diabetes, n (%) 953 (27.7) 479 (37.2) <0.001
Glucose (mmol/L) 5.25 ± 1.5 5.61 ± 1.61 <0.001
Glucose ≥ 6.1 mmol/L, n (%) 171 (14.8) 174 (24.9) <0.001
TG (mmol/L) 1.56 ± 0.59 1.58 ± 0.55 <0.001
TG ≥ 1.71 mmol/L, n (%) 398 (34.5) 252 (36.1) 0.503
TC (mmol/L) 4.4 ± 0.64 4.58 ± 0.75 <0.001
TC ≥ 5.2 mmol/L, n (%) 136 (11.8) 154 (22.0) <0.001
HDL–C (mmol/L) 1.06 ± 0.22 1.03 ± 0.19 <0.001
HDL–C < 1.04 mmol/L, n (%) 610 (52.9) 313 (44.8) 0.001
LDL–C (mmol/L) 2.32 ± 0.53 2.52 ± 0.62 <0.001
LDL–C ≥ 3.1 mmol/L, n (%) 97 (8.4) 127 (18.2) <0.001
Table 1. Demographic and clinical characteristics of patients with acute coronary syndrome (ACS) patients and 
healthy control group. Continuous variables are expressed as mean ± SD. Categorical variables are expressed as 
percentages. BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL–C, high–density lipoprotein–
cholesterol; LDL–C, low density lipoprotein–cholesterol. *One participant was missing the measurement of height.
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Univariate regression analysis showed that the C allele in rs755622 was the risk factor for ACS (CG and CC 
genotype vs. GG genotype, OR = 1.306, 95% CI, 1.078–1.581, P = 0.006). Multivariate logistic regression analysis 
was further used to detect the association between rs755622 polymorphisms and susceptibility of ACS. After 
adjusting the confounding factors including age, gender, BMI, smoking, hypertension, diabetes, TG, TC, HDL–C 
and LDL–C, the C allele remained the independent risk factor for ACS (CG and CC genotype vs. GG genotype, 
AOR = 1.278, 95% CI, 1.042–1.567, P = 0.019, Table 3). However, no difference was observed in the other two 
SNPs.
Plasma MIF levels significantly associated with MIF gene rs755622 polymorphisms. The rela-
tionship between plasma MIF levels and MIF gene rs755622 polymorphisms (GG, CG and CC genotypes) were 
further evaluated. CC genotype carriers had the highest plasma levels of MIF than CG and GG genotype carriers. 
The MIF level in ACS patients with CC genotype was 6.5% and 15.6% higher than that in ACS patients carrying 
CG and GG genotypes, respectively. MIF levels in ACS patients carrying C allele (both in CG and CC pheno-
types) were also significantly higher than healthy controls carrying the same phenotypes (Fig. 1, all P < 0.05).
Discussion
Many factors involve in the development and progression of the coronary artery atherosclerosis. Inflammation 
is one of the most important risk factors in the pathogenesis of ACS. Variations in multiple genes involved in 
inflammation, and previous studies showed that there were close relationships between PPARα, interleukin 18 
(IL-18), IL-1β, SIRT2, and CD14 receptor and incidence of acute myocardial infarction24–27. In the present study, 
we found the polymorphism (rs755622) of MIF gene was significantly associated with the risk of ACS in Chinese 
Han population.
MIF was initially identified more than 6 decades ago as T-cell–derived cytokine with a function to inhibit 
random migration of macrophages in vitro28. Over the years, MIF has been generally believed to be a multifaceted 
cytokine and a critical mediator of the host immune response and inflammation. Previous studies show that MIF 
is a key modulator which promotes and modulates the magnitude of the acute inflammatory response, such as 
acute lung injury29, acute kidney injury30, acute adipose tissue inflammation31 and acute rheumatic fever32. MIF 
has been also proved to be associated with vulnerability of atherosclerotic plaque9,33. Several studies have docu-
mented that MIF regulates inflammatory cell recruitment to lesion areas through interaction with the chemokine 
receptors CXCR2 and CXCR434. MIF is highly expressed in vulnerable plaques and it can enhance expression 
and activity of matrix metalloproteinases (MMPs), thereby contributing to destabilization of the atherosclerotic 
plaque34,35.
In this case–control study, we evaluated the associations between the MIF genetic variants (rs755622, 
rs1007888, and rs2096525) and ACS in Chinese Han population living in Xinjiang. We found that participants 
with rs755622 GC and CC genotypes were more susceptible to ACS than those with GG genotype allele after 
adjustments for potential confounding factors. A similar finding was also reported in a small case-control study 
conducted in other Chinese population36. Our previous study reported that Chinese Kazakh carrying MIF 
rs755622 CC genotype or C allele had an increased risk of CAD13. Some studies conducted in other races also 
found a close association between MIF gene polymorphism and CAD. In ONICA/KORA case-cohort study, car-
riers of the minor alleles rs755622C and rs2070766G had a higher risk for incident CAD in southern Germany37. 
Polymorphisms
Control ACS P-
Valuen = 1153 n = 699
rs755622
GG 727 (63.1%) 396 (56.7%)
0.024CG 382 (33.1%) 272 (38.9%)
CC 44 (3.8%) 31 (4.4%)
G allele 1836 (79.6%) 1064 (76.1%)
0.012
C allele 470 (20.4%) 334 (23.9%)
rs1007888
AA 273 (23.7%) 150 (21.5%)
0.264AG 574 (49.8%) 375 (53.6%)
GG 139 (23.1%) 84 (26.3%)
A allele 1120 (48.6%) 675 (48.3%)
0.866
G allele 1186 (51.4%) 723 (51.7%)
rs2096525
TT 694 (60.2%) 426 (60.9%)
0.736CT 413 (35.8%) 250 (35.8%)
CC 46 (4.0%) 23 (3.3%)
T allele 1801 (78.1%) 1102 (78.8%)
0.603
C allele 505 (21.9%) 296 (21.2%)
Table 2. Association analyses between genotypes and alleles of the MIF gene polymorphisms in patients with 
acute coronary syndrome (ACS) and in healthy control group.
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In a western Mexican population, association between MIF -794 (CATT)5-8 polymorphism and susceptibility of 
ACS was detected14. This information indicates that MIF is a promising genetic marker for predicting the risk of 
CAD. However, some negative findings were also reported. A study conducted in Czech and Russian population 
failed to detect a significant difference in the distribution of MIF -173G/C genotypes, alleles or carriage rates 
between patients with myocardial infarction and control groups38. The lack of association between CAD class 
and MIF -794 (CATT)5-8 polymorphisms with soluble MIF levels in a small number of CAD subjects (n = 70) 
was reported39. Although the reason for these discrepant results is not defined, it may be due to the difference in 
the stage of CAD and phenotypic variance, therefore a large scare of clinical study is warranted to confirm the 
universal implication of MIF gene polymorphism in predicting the risk of CAD.
Further, in the present study, we also measured plasma MIF levels in part of ACS patients and healthy con-
trols. We found that CC phenotype carriers had the highest MIF levels. MIF levels in ACS patients carrying C 
allele (both in CG and CC phenotypes) were significantly higher than healthy controls carrying the same pheno-
types and also higher than ACS patients carrying GG phenotype. Similar findings were also reported in a small 
case-control study with a higher plasma MIF level in MIF-173C carriers than in MIF-173G carriers36. Another 
study including 138 ACS and 98 stable angina pectoris (SAP) patients documented that ACS patients had signifi-
cantly higher plasma MIF levels compared with SAP patients33. In both ACS and SAP patients, plasma MIF levels 
increased in conjunction with the extent of complex lesions33. Our previous study in Chinese Kazakh population 
also revealed that CAD patients with rs755622 C allele (CC and CG genotype) have higher levels of Gensini score 
when compared to C allele noncarriers13. These findings further demonstrate the functional link between MIF 
gene polymorphism, especially -173C (rs755622) carrying and associated MIF production during occurrence of 
ACS and CAD and the severity of coronary lesion. Indeed, our previous study showed that plasma MIF levels in 
Characteristics N COR (95% CI) P AOR (95% CI) P
rs755622
GG 1123 Ref.
CG + CC 729 1.306 (1.078–1.581) 0.006 1.278 (1.042–1.567) 0.019
Age 1852 1.009 (0.995–1.013) 0.409
Gender
Female 786 Ref.
Male 1066 1.312 (1.083–1.589) 0.005 1.086 (0.842–1.402) 0.524
Smoking
No 579 Ref.
Yes 1273 1.548 (1.267–1.892) <0.001 1.498 (1.153–1.946) 0.002
BMI ≥ 24 kg/m2
No 525 Ref.
Yes 1326 1.419 (1.146–1.758) 0.001 1.257 (0.997–1.584) 0.053
Hypertension
No 785 Ref.
Yes 1067 1.671 (1.382–2.021) <0.001 1.294 (1.054–1.591) 0.014
Diabetes
No 420 Ref.
Yes 1432 2.189 (1.755–2.729) <0.001 3.692 (2.754–4.949) <0.001
Glucose ≥ 6.1 mmol/L
No 1507 Ref.
Yes 354 1.903 (1.503–2.410) <0.001 1.045 (0.790–1.381) 0.760
TG ≥ 1.71 mmol/L
No 1202 Ref.
Yes 650 1.069 (0.879–1.302) 0.503
TC ≥ 5.2 mmol/L
No 290 Ref.
Yes 1562 2.113 (1.641–2.721) <0.001 1.975 (1.504–2.594) <0.001
HDL-C < 1.04 mmol/L
No 923 Ref.
Yes 929 0.722 (0.598–0.872) 0.001 0.832 (0.679–1.020) 0.077
LDL-C ≥ 3.1 mmol/L
No 1761 Ref.
Yes 89 3.462 (2.207–5.430) <0.001 1.965 (1.443–2.675) <0.001
Table 3. Univariate and multivariate analysis of effects of MIF SNP rs755622 and characteristics of subjects 
on the risk of acute coronary syndrome. BMI, body mass index; TG, total triglyceride; TC, total cholesterol; 
HDL–C, high–density lipoprotein–cholesterol; LDL–C, low density lipoprotein–cholesterol; COR, crude odds 
ratio; AOR, adjusted odds ratio.
6Scientific RepoRtS |          (2020) 10:140  | https://doi.org/10.1038/s41598-019-56949-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
ST-segment elevated myocardial infarction (STEMI) correlated with cardiac magnetic resonance (CMR)-derived 
infarct size, ventricular volumes and ejection fraction, suggesting that plasma MIF levels are predictive of final 
infarct size and the extent of cardiac remodeling10.
Taken together, MIF gene polymorphism in general population may bear predictive value for the risk of CAD, 
while in ACS or CAD patients MIF gene polymorphism with CC genotype and C allele carrying in conjunction 
with plasma MIF levels may add values for predicting the severity of CAD and even prognosis.
Study Limitations. There are several limitations in this study. First, we only studied the association between 
three SNP of MIF gene (rs755622, rs1007888 and rs2096525) and risk of ACS in Chinese Han population in 
Xinjiang and did not cover the other variations of the MIF gene such as -794 (CATT)5-8 MIF polymorphism. 
Second, the study population is relative small although it is the largest scare so far. A large and long-term follow-up 
study is necessary to solidate the clinical values. Third, we only measured plasma MIF levels in a small portion of 
study participants which may also limit the generalisation of our findings.
In conclusion, our findings indicate that MIF gene rs755622 variant with CC genotype and C allele is associ-
ated with increased risk of ACS. Identification of this MIF gene polymorphism may help for predicting the risk 
of ACS.
Data availability
The datasets analyzed during the current study including accession information for the raw genotyping data are 
available from the corresponding author on reasonable request.
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